A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients

Archives of Ophthalmology

Volumn 122, Issue 11, 2004, Pages 1680-1685

  Albert, Daniel M ^a,d   Gangnon, Ronald E ^a   Zimbric, Michele L ^a   Damico, Christine M ^a   Fisher, Marian R ^a   Gleiser, Joel ^a   Grossniklaus, Hans E ^b   Green, W Richard ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; LATANOPROST; PROSTAGLANDIN DERIVATIVE;

ANAMNESIS; ARTICLE; CELL COUNT; CELL FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA STROMA; DESCEMET MEMBRANE; EYE COLOR; EYE SYNECHIA; FEMALE; FIBROBLAST; GLAUCOMA; GLAUCOMA SURGERY; HEALTH CENTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAOCULAR HEMORRHAGE; IRIDECTOMY; IRIS; IRIS RUBEOSIS; KERATITIS; LENS CAPSULE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; MITOSIS RATE; OCULAR BLOOD VESSEL; OPHTHALMOLOGY; PIGMENT DISORDER; PIGMENT EPITHELIUM; PRECANCER; PREVALENCE; PRIORITY JOURNAL; PSEUDOEXFOLIATION; VASCULAR DISEASE;

ANTIHYPERTENSIVE AGENTS; EYE COLOR; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; IRIDECTOMY; IRIS; MALE; MELANINS; MELANOCYTES; MELANOSIS; PROSTAGLANDINS F, SYNTHETIC;

EID: 8144223149     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.11.1680     Document Type: Article

References (27)

1. Stjernschantz JW, Albert DM, Hu D, Drago F, Wistrand PJ. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 2002;47:S162-S175.
2. Tsai JC, Sivak-Callcott JA, Haik BG, Zhang J, McLean IW. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report. J Glaucoma. 2001;10:411-413.
3. Grierson I, Pfeiffer N, Cracknell KP, Appleton P. Histology and fine structure of the iris and outflow system following latanoprost therapy. Surv Ophthalmol. 2002;47:S176-S184.
4. Yanoff M, Fine BS. Ocular Pathology: A Textand Atlas. 2nd ed. Philadelphia, Pa: Harper & Row Publishers; 1982:822.
5. Wilkerson CL, Syed NS, Fisher MR, Robinson NL, Wallow IH, Albert DM. Melanocytes and iris color: light microscopic findings. Arch Ophthalmol. 1996;114:437-442.
6. Eagle RC Jr. Iris pigmentation and pigmented lesions: an ultrastructural study. Trans Am Ophthalmol Soc. 1988;86:581-687.
7. Imesch PD, Bindley CD, Khademian Z, et al. Melanocytes and iris color: electron microscopic findings. Arch Ophthalmol. 1996;114:443-447.
8. Albert DM, Green WR, Zimbric ML, et al. Iris melanocyte numbers in Asian, African-American, and Caucasian irides. Trans Am Ophthalmol Soc. 2003;101:217-222.
9. Imesch PD, Wallow IH, Albert DM. The color of the human eye: a review of the morphologic correlates and of some conditions that affect iridial pigmentation. Surv Ophthalmol. 1997;41:S117-S123.
10. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(suppl 2):S129-S138.
11. Teus MA, Arranz-Marquez E, Lucea-Suescun P. Incidence of iris colour change in latanoprost treated eyes. Br J Ophthalmol. 2002;86:1085-1088.
12. Camras CB, Wax MB, Ritch R, et al. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. Am J Ophthalmol. 1998;126:390-399.
13. Lindsey JD, Jones HL, Hewitt EG, Angert M, Weinreb RN. Induction of tyrosinase gene transcription in human iris organ cultures exposed to latanoprost. Arch Ophthalmol. 2001;119:853-860.
14. Drago F, Marino A, La Manna C. Alpha-methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp Eye Res. 1999;68:85-90.
15. 2α and latanoprost on cultured human iridial melanocytes. Exp Eye Res. 2000;70:113-120.
16. Stjernschantz J, Ocklind A, Wentzel P, Lake S, Hu DN. Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes. Acta Ophthalmol Scand. 2000;78:618-622.
17. Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 2000;70:563-569.
18. Lindquist NG, Larsson BS, Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp Eye Res. 1999;69:431-436.
19. Selen G, Stjernschantz J, Resul B. Prostoglandin-induced iridial pigmentation in primates. Sun Ophthalmol. 1997;41(suppl 2):S125-S128.
20. Prota G, Vincensi MR, Mapolitano A, Selen G, Stjernschantz J. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment Cell Res. 2000;13:147-150.
21. Zhan GL, Toris CB, Camras CB, Wang YL, Bito LZ. Prostaglandin-induced iris color darkening: an experimental model. Arch Ophthalmol. 1998;116:1065-1068.
22. Grierson I, Lee WR, Albert DM. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Arch Ophthalmol. 1999;117:394-396.
23. Grierson I, Cracknell KP, Pfeiffer N. The iris after prostanoid treatment. Curr Opin Ophthalmol. 2001;12:112-118.
24. Pfeiffer W, Grierson I, Goldsmith H, Hochgesand D, Winkgen-Bohres A, Appleton P. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study. Arch Ophthalmol. 2001;119:191-196.
25. De Asua LJ, Clingan D, Rudland PS. Initiation of cell proliferation in culture mouse fibroblasts by prostaglandin F2alpha. Proc Natl Acad Sci U S A. 1975;72:2724-2728.
26. Black FM , Wakelam MJ. Activation of inositol phospholipid breakdown by prostaglandin F2 alpha without any stimulation of proliferation in quiescent NIH-3T3 fibroblasts. Biochem J. 1990;266:661-667.
27. Conconi MT, Spinazzi R, Tommasini M, Limoli A, Parnigotto PP. Prostaglandin F2 alpha can modulate the growth and the differentiation of bovine corneal epithelial cells cultured in vitro. Ann Anat. 2001;183:567-573.